J.P. Morgan Healthcare Conference

  • Analyzing Eli Lilly's drug pipeline

    CNBC's Meg Tirrell speaks to John Lechleiter, Eli Lilly CEO, about the strength and outlook for the health care sector, and what new drugs he's most excited about.

  • Great day for Foundation Medicine: CEO

    CNBC's Meg Tirrell, and Michael Pellini, Foundation Medicine president & CEO, discuss the benefits of Roche's majority stake in Foundation Medicine.

  • The JPMorgan health care conference hadn't even officially begun when the first big piece of news of the week hit: Irish drugmaker Shire said Sunday morning it's purchasing orphan-drug company NPS Pharmaceuticals for $5.2 billion.

  • Ariad

    History says the best play is to buy biotech stocks the day before the JPMorgan meeting starts and hold until the end.

  • JPM's health care summit preview

    CNBC biotech and pharma reporter Meg Tirrell looks at what to expect from the biggest and most important health care conference of the year. The 33rd annual J.P. Morgan Health Care Conference starts Monday, with 450 companies presenting to almost 9,000 attendees.

  • Biotech investor Brad Loncar is on a mission to persuade every presenting company at an upcoming biotech conference to also webcast its breakout session.

  • Stock moving information kept behind doors

    CNBC's Meg Tirrell provides insight to the debate over transparency from biotech companies. Biotech investor Brad Loncar, thinks this is just an awareness issue.

About J.P. Morgan Healthcare Conference

  • The J.P. Morgan Healthcare Conference is the biggest health care investing event of the year.

Health and Science

Latest Special Reports

  • Innovative female entrepreneur examining prototype

    In an era of rapid technological advances and demographic change, how do legacy companies adapt, innovate and evolve? CNBC Evolve features iconic global companies and executives who are embracing change and transforming for the future.

  • CNBC Upstart 100 is a new original list of the bright young startups poised to become the great companies of tomorrow.

  • Frontline insights and unique views on key issues and challenges facing today’s CFOs.